22.7% weight loss yet Novo Nordisk stock drops 27%

Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.

chemical:semaglutide

Semaglutide & Liraglutide continue to be effective

Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.

category:watercooler

Lizzo's as a lens on GLP1 public opinion

We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.

company:eli-lilly

Eli Lilly brands GLP1s as "anti-hedonics"

Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"

category:watercooler

How much are people paying for GLP1s? (2024/11)

We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.

category:factsheet

A list of FDA approved GLP1s

A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.

category:side-effects

Anxiety and suicidal thoughts after stopping GLP1s?

Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.

government

Biden-Harris administration keen on GLP1s

The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.

category:watercooler

Weight loss "stalling" on GLP1s?

What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.

country:uk

The UK's bet on GLP1

A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.

research

Research on GLP1 Signaling in the brain

How does GLP1 signal the brain? We take a look at related research to try and learn more.

GLP1s and Osteoarthritis

Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.

category:news

Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024

At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.

category:side-effects

Semaglutide's link to blinding disease (NAION)

We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.

category:factsheet

Patent expirations for GLP1 Receptor Agonists

How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.

category:news

FDA reconsidering Tirzepatide shortage list removal

After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.

category:news

Compounders sue FDA over Tirzepatide shortage changes

Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?

category:news

Why the Tirzepatide shortage ending might be bad news.

Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.

category:news

GLP1s and Sleep Apnea

GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea

Habener, Mosjov and Knudsen win the Lasker award

The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.

category:news

Insurers continue to embrace Virtual Healthcare for GLP1s

Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.

categeory:watercooler

Novo's CEO will testify, but change is unlikely

Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.

categeory:watercooler

Reminder: Ozempic face isn't real

Ozempic face isn't real -- fast weight loss causes changes to the skin, and your face is a prime area that will change.

drug:am-133

Amgen's GLP1: MariTide (formerly AMG-133)

Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.

company:eli-lilly

Eli Lilly's other new GLP1 - Orforglipron

Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.